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The usefulness of esmolol in predicting the efficacy of treatment 
with an oral beta-adrenergic blocking agent was evaluated in 27 
consecutive patients with neurocardiogenic syncope. Seventeen 
patients had a positive head-up tilt test response at baseline and 10 
patients required intravenous isoproterenol for provocation of 
hypotension. All patients were then given a continuous esmolol 
infusion (500 JLg/kg per min loading dose for 3 min followed by 
300 Jlg/kg per min maintenance dose) and rechallenged with a 
head-up tilt test at baseline or with isoproterenol. 
Of the 17 patients with a positive baseline tilt test response, 11 
continued to have a positive response to esmolol challenge. Sixteen 
patients (including all10 patients with a positive tilt test response 
with isoproterenol) exhibited a negative response to upright tilt 
during esmolol infusion. 
Syncope, defined as transient loss of consciousness, is 
responsible for up to 3% of all emergency room visits in the 
United States (1). Because of the intermittent and episodic 
nature of syncope, a definitive etiology is difficult to docu-
ment and the use of noninvasive techniques is frequently 
unrewarding (2). Recently, the head-up tilt test alone or with 
isoproterenol challenge has been used as a diagnostic 
method in a subset of patients with unexplained syncope 
(3-6). In these patients, neurocardiogenic mechanisms seem 
to be the underlying cause of syncope that may respond to 
treatment with an oral beta-adrenergic blocking agent (7). 
The future efficacy of such agents in patients with neuro-
cardiogenic syncope is difficult to predict at the initial tilt 
test. This study was designed to determine if intravenous 
esmolol, an ultrashort-acting cardioselective beta-blocker, 
would help in assessing the response of patients with neuro-
cardiogenic syncope to long-term oral beta-blocker therapy. 
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Irrespective of their response to esmolol infusion, all patients 
had a follow-up tilt test with oral metoprolol after an interval of 
~5 half-lives of the drug. All 16 patients (100%) with a negative 
tilt test response during esmolol infusion had a negative tilt test 
response with oral metoprolol. Of the 11 patients with a positive 
tilt test response during esmolol infusion, 10 (90%) continued to 
have a positive response with oral metoprolol. 
It is concluded that in the electrophysiology laboratory, es-
molol can accurately predict the outcome of a head-up tilt 
response to oral metoprolol. This information may be helpful in 
formulating a therapeutic strategy at the initial head-up tilt test in 
patients with neurocardiogenic syncope. 
(JAm Coli Cardio/1992;19:402-8) 
Methods 
Study patients. Twenty-seven consecutive patients (18 
female and 9 male, 12 to 75 years of age) were included in 
this study. All patients were referred for evaluation of 
unexplained syncope and had a positive head-up tilt test 
response at baseline study (17 patients) or after intravenous 
administration of isoproterenol (10 patients). Twenty-six 
patients had two or more episodes and one patient had one 
episode of syncope in the preceding year. In addition, 20 
patients had a history of recurrent presyncope. Comprehen-
sive physical examination, neurologic evaluation, surface 
electrocardiogram (ECG) and electrophysiologic evaluation 
did not identify the cause of syncope in any of these patients. 
Two patients had coronary artery disease. The mean ejec-
tion fraction was 63.2% (range 45% to 73%). 
Head-up tilt test. During the head-up tilt test, arterial 
blood pressure was monitored by means of an intraarterial 
cannula inserted percutaneously into the brachial or femoral 
artery. Each patient was tilted to 70° for a maximum of 
15 min. If the baseline tilt test response was negative, the 
patient was returned to the supine position and intravenous 
isoproterenol infusion was started at 1 JLg/min. The infusion 
rate was gradually increased until a 20% increase in heart 
rate was achieved and the head-up tilt test was repeated. 
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Table 1. Clinical and Electrophysiologic Characteristics of 27 Patients 
Syncope Results of HUT 
Pt Age (yr)/ Heart Provocation 
No. Gender Disease (min to provocation) Esmolol Metoprolol 
58/M 
2 40/F 
3 40/M 
4 33/F 
5 15/F 
6 75/F 
7 58/F 
8 73/F 
9 37/F 
10 40/F 
11 12/M 
12 35/F 
13 71/F 
14 43/M 
15 38/F 
16 38/F 
17 34/F 
18 39/F 
19 55/M 
20 42/M 
21 20/M 
22 22/F 
23 72/F 
24 71/F 
25 43/M 
26 63/M 
27 54/F 
NSHD 
NSHD 
NSHD 
NSHD 
NSHD 
NSHD 
NSHD 
NSHD 
NSHD 
NSHD 
NSHD 
NSHD 
NSHD 
NSHD 
NSHD 
NSHD 
NSHD 
NSHD 
NSHD 
NSHD 
NSHD 
NSHD 
CAD 
NSHD 
NSHD 
CAD 
NSHD 
HUT (10) 
HUT (15) 
HUT (6) 
HUT (7) 
HUT (14) 
HUT(S) 
HUT and Iso (8) 
HUT and Iso (14) 
HUT and Iso (6.5) 
HUT and Iso (6) 
HUT and lso (5.5) 
HUT and lso (9) 
HUT and lso (3) 
HUT and lso (6.5) 
HUT and lso (3.5) 
HUT and Iso (8) 
HUT(6) 
HUT(6.5) 
HUT(6) 
HUT(3) 
HUT(2) 
HUT (10) 
HUT(7) 
HUT (10) 
HUT(5) 
HUT(7) 
HUT(3) 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
CAD = coronary artery disease; F = female; HUT = head-up tilt test; Iso = isoproterenol; M = male; 
NSHD = no structural heart disease; Pt = patient; - = negative head-up tilt test response; + = positive tilt test 
response. 
A response was considered positive if significant arterial 
hypotension in association with syncope or presyncope was 
encountered. All patients with a positive tilt test response 
then received an infusion of esmolol at 500 p.g/kg for 3 min 
followed by a maintenance dose of 300 JLg/kg per min. Five 
minutes after the start of the infusion, patients were rechal-
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lenged with head-up tilt alone or with isoproterenol as 
before. All patients, irrespective of the results with esmolol, 
were then started on treatment with oral metoprolol. 
Twenty-six patients received metoprolol, 50 mg twice daily, 
and one patient who weighed 46 kg received 25 mg twice 
daily. After ;;::5 half-lives of the drug, the head-up tilt test 
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Figure 1. Mean arterial pressure at initi-
ation (lnit.) and termination (Term.) of 
the head-up tilt test at baseline tilt (left 
panel), during esmolol infusion (middle 
panel) and with oral metoprolol (right 
panel) in 16 patients who demonstrated a 
negative response to the head-up tilt test 
during esmolol challenge. The slight de-
crease in arterial pressure during esmolol 
infusion is insignificant as compared with 
the baseline level. Furthermore, none of 
the patients had syncope or presyncope 
and in no patient was the decrease in 
arterial pressure during esmolol chal-
lenge > 13 mm Hg. Similarly, arterial 
pressure changes with metoprolol were 
insignificant in comparison with the level 
during baseline tilt. 
I nit. Term. I nit. Term. lnit. Term. 
BASELINE ESMOLOL METOPROLOL 
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was repeated under similar circumstances as before (that is, 
at baseline study or after intravenous isoproterenol). 
Statistical analysis. The data are expressed as mean val-
ues ± SD. Paired and unpaired t test analysis was used to 
compare heart rate and blood pressure within the same 
group and between different groups. A p value < 0.05 was 
considered significant. 
Results 
Patient characteristics. Table 1 shows the clinical and 
electrophysiologic characteristics of the 27 patients included 
in this study. Two patients had documented sinus pauses 
(3 .5 to 6 s duration), one had complete heart block and two 
had significant sinus bradycardia and syncope while being 
monitored in the hospital for earlier episodes of syncope that 
had occurred outside the hospital. 
Seventeen patients had a positive baseline head-up tilt 
test response and 10 required intravenous isoproterenol (I to 
3 pg/min, mean 1. 7) for provocation of hypotension and 
syncope or presyncope. The mean time to a positive head-up 
tilt test response at baseline was 7.4 ± 3.4 min (range 2 to 
w 
a: +60 0 HUT, Baseline E Q, +60 
;:) a HUT+ Esmolol .a ~ c; +40 
- HUT + Metoprolol +40 
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Figure 2. Heart rate changes in the 16 pa-
tients who had a negative head-up tilt re-
sponse during esmolol infusion. A signifi-
cant decrease in heart rate was seen at 
baseline tilt, with one patient having asys-
tole. In comparison, a minimal increase or 
no significant change was seen when the 
same patients were rechallenged with a 
head-up tilt test during esmolol infusion and 
subsequently with oral metoprolol. Format 
and abbreviations as in Figure 1. 
15). The mean time to a positive head-up tilt test with 
isoproterenol provocation was 6.8 ± 3.2 min (range 2 to 15). 
Patients with a negative head-up tilt test response during 
esmolol infusion. Changes in mean arterial pressure and 
heart rate during the head-up tilt test at baseline, during 
esmolol infusion and during oral metoprolol therapy are 
depicted in Figures 1 and 2. A decrease in mean arterial 
pressure of 43 ± 13 mm Hg at baseline from the initial 
upright position to termination of the tilt test was signifi-
cantly greater than the change recorded during esmolol 
infusion (-5 ± 5 mm Hg; p < 0.00001 vs. baseline tilt) or 
with oral metoprolol (I ± 7 mm Hg; p < 0.00001 vs. baseline 
tilt) (Fig. 3). Furthermore, none of these patients had syn-
cope or presyncope when rechallenged with head-up tilt 
during esmolol infusion or oral metoprolol. Similarly, heart 
rate during baseline tilt decreased in all patients except two, 
with Patient 5 having asystole (Fig. 4). A decrease in heart 
rate of 23 ± 21 beats/min at baseline tilt was significant in 
comparison with the change during esmolol infusion (8 ± 13 
beats/min; p < 0.0004 vs. baseline tilt) and during oral 
metoprolol therapy (4 ± 14 beats/min; p < 0.0008 vs. 
baseline tilt) (Fig. 3). 
Figure 3. Mean maximal changes in mean ar-
terial pressure (left panel) and heart rate (right 
panel) in the 16 patients who demonstrated a 
negative head-up tilt (HUT) response during 
esmolol infusion. In comparison with baseline 
tilt, insignificant changes in mean arterial pres-
sure and heart rate are seen during esmolol and 
z:t: a: ..___, ...___, oral metoprolol challenge. 
c((.) -80 ...___, ........._, 1- -80 p<0.0004 pzNS 
w p < 0.00001 p < 0.01 a: p<O.OOOB 
:E -100 p<0.00001 c(- 100 w 
:1: 
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Patients with a positive head-up tilt test response during 
esmolol infusion. Eleven patients with a positive baseline 
head-up tilt test response continued to exhibit a positive 
response during esmolol infusion. All of these patients 
except Patient 17 continued to show a positive response 
when rechallenged with head-up tilt after an interval of ~5 
half-lives of oral metropolol. 
Mean arterial pressure and heart rate changes from the 
initial upright position to termination of the tilt test at 
baseline, during esmolol infusion and with oral metoprolol 
are shown in Figures 5 and 6. The magnitude of the decrease 
in mean arterial pressure at baseline tilt (-54 ± 22 mm Hg) 
was similar to that seen during esmolol infusion ( -40 ± 
12 mm Hg) and with oral metoprolol (-48 ± 20 mm Hg). 
70 
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115/75 
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50 mg Bid 
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Figure 4. Patient 5. Negative head-up tilt response to esmolol 
infusion and oral metoprolol. From top to bottom, tracings represent 
surface electrocardiographic lead V1 and arterial pressure. The heart 
rate (HR) and blood pressure (BP) at the initiation of head-up tilt are 
depicted in panel A. At 14 min (panel B), cardiac asystole ensues, 
lasting for 9 s. After resumption of the supine position and stabili-
zation of heart rate and blood pressure, a repeat head-up tilt test 
during esmolol infusion shows a normal response (panels C and D). 
Similarly, a negative tilt test response is seen after 3 days of oral 
metoprolol therapy (panels E and F). 
Similarly, differences in the decrease in heart at baseline tilt 
(-27 ± 36 beats/min), during esmolol infusion ( -13 ± 25 
beats/min) and with oral metoprolol ( -18· ± 26 beats/min) 
were insignificant (Fig. 7). 
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There were no significant differences in age (44 ± 18 vs. 
46 ± 17 years) or ejection fraction (62 ± 14% vs. 64 ± 13%) 
between the groups with a negative or positive head-up tilt 
test response during esmolol infusion. 
Baseline heart rate (72 ± 14 vs. 74 ± 10 beats/min) was 
similar between the groups with a negative and or positive 
head-up tilt test response during esmolol infusion. Similarly, 
mean maximal changes in heart rate from the supine to the 
initial upright position (21 ± 14 vs. 19 ± 19 beats/min) and 
from the supine to the upright position during 70° upright tilt 
positioning (32 ± 19 vs. 28 ± 26 beats/min) did not differ 
between the two groups. Mean maximal changes in heart 
rate during esmolol infusion from the supine to the upright 
position also did not differ between the two groups (11 ± 13 
vs. 12 ± 10 beats/min). 
Discussion 
The head-up tilt test. This study highlights the usefulness 
of esmolol in combination with the head-up tilt test in 
predicting patient response to long-term oral beta-blocker 
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Figure 6. Heart rate changes in the 11 pa-
tients who continued to have a positive 
head-up tilt test response during esmo1ol infu-
sion. Changes in heart rate at baseline tilt, 
during esmolol infusion and with oral meto-
prolol were significant. Two patients had 
asystole at baseline tilt and with oral meto-
prolol. One of these patients also had asystole 
on esmolol. The broken line is as defined in 
Figure 5. Format and abbreviations as in 
Figure I. 
therapy. Head-up tilt testing is increasingly being used as a 
diagnostic tool in patients with unexplained syncope; previ-
ous reports (4) have shown its high reproducibility rate in 
such patients. In most patients, the phenomenon of neuro-
cardiogenic syncope is characterized by prodromal symp-
toms of pallor, yawning, nausea and sweating; in others, loss 
of consciousness may be abrupt. We recently reported (7) on 
the long-term efficacy of oral beta-blocker and disopyramide 
therapy in patients with unexplained syncope and a positive 
head-up tilt test response. However, not all patients respond 
to initial therapy and it may actually worsen the presenting 
symptoms in some (Fig. 8). Because of the potential for 
serious injury and incapacitating symptoms, it is imperative 
that an effective therapeutic strategy be identified at the 
initial test. 
Beta-blocker therapy and neurocardiogenic mechanisms of 
syncope. Using esmolol challenge, we identified two distinct 
groups with a favorable or unfavorable response to oral 
beta-blocker therapy at the initial tilt test in our study. It is 
unclear how beta-blockers prevent hypotension and brady-
cardia in patients with neurocardiogenic syncope. Several 
Figure 7. Mean maximal changes in mean ar-
terial pressure (left panel) and heart rate (right 
panel) in the 11 patients who continued to 
demonstrate a positive head-up tilt (HUT) re-
sponse during esmolol infusion. Changes in 
mean arterial pressure and heart rate at base-
line tilt, during esmolol infusion and with oral 
metoprolol are significant and almost of the 
same magnitude. Format as in Figure 3. 
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animal experiments (8-13) have suggested that propranolol 
can decrease the discharge frequency of mechanoreceptors 
that are thought to initiate hypotension and bradycardia in 
susceptible persons. The investigators reported that this 
effect of propranolol was maintained even with isoproteronol 
and during increased left ventricular end-diastolic pressure 
when maximal mechanoreceptor activity was demonstrated. 
We recently demonstrated (14) a significant increase in 
epinephrine concentrations with little or no change in nor-
epinephrine levels at the time of tilt-induced hypotension in 
patients with neurocardiogenic syncope. Echocardiographic 
data from our laboratory (15) have also suggested that a 
marked increase in left ventricular fractional shortening 
along with a decrease in left ventricular systolic volume 
always preceded the onset of hypotension in these patients. 
From these observations, it is thus conceivable that beta-
blockers by their negative inotropic effect may at least 
partially inhibit the mechanoreceptor activity that is trig-
gered by ventricular deformity and stretch. 
Sixteen patients had a negative head-up tilt test response 
during esmolol infusion and 11 patients continued to show a 
positive response to upright tilt during the infusion. The 
underlying reason for these interpatient differences is un-
r 125-100 3 75 3 .. ~ .. -0 
(Syncope) Asystole : 11 .5 seconds 
r 125-100 3 T5 3 .. :z: G .. -0 
(Syncope) Asystole : 13 seconds 
Figure 8. Patient 25. Positive head-up tilt test response after esmolol 
infusion and oral metoprolol. Panel I shows the heart rate (HR) and 
blood pressure (BP) response during baseline head-up tilt (A, B and 
C). At 5 min, the patient has 11 s of asystole. After resumption ofthe 
supine position and stabilization of heart rate and blood pressure, 
the patient is rechallenged with esmolol and the head-up tilt test is 
repeated (panel 11). Cardiac asystole again ensues at 3.5 min (F). 
After 5 days of oral metoprolol therapy, the tilt test is repeated as 
before (panel Ill). As depicted, the patient becomes syncopal and 
cardiac asystole again ensues 6 min after the start of the head-up tilt 
test. 
clear. All patients with a positive head-up tilt test response 
with isoproterenol had a negative response during esmolol 
infusion. However, no other significant differences were 
demonstrated between the two groups. Significant bradycar-
dia and asystole in some patients and hypotension preceding 
bradycardia in the majority of the patients during the base-
line positive tilt test response were seen in both groups of 
patients (Fig. 7 and 8). Baseline supine heart rate and mean 
maximal changes in heart rate from the supine to the upright 
position at baseline tilt and with esmolol were similar be-
tween the two groups. 
Because the esmolol dose was titrated according to body 
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weight, variations in dose could not have accounted for the 
differences in response. Furthermore, all patients who re-
quired isoproterenol for provocation of hypotension and 
syncope after a negative baseline head-up tilt test response 
had a negative response with esmolol and oral metoprolol. 
These observations suggest that hypersensitivity of the 
mechanoreceptors rather than the increased adrenergic tone 
may determine which patients will respond favorably to 
beta-blockers. 
Head-up tilt response to esmolol and metoprolol. Esmolol 
quite accurately predicted the outcome of oral metoprolol 
therapy in our patients. In contrast, intravenous metoprolol 
at the initial tilt test has been ineffective in predicting the 
response to oral beta-blockers in patients with neurocardio-
genic syncope (16). This discordant response of patients 
receiving intravenous metoprolol or esmolol may be due to 
several factors. Metoprolol is a lipid-soluble beta-blocker 
with a large volume of distribution (that is, 4.2 ± 0. 7 
liters/kg) (17,18). After intravenous administration, its initial 
distribution may be favored to tissues with a high blood flow 
and lipid content. This may cause a delay in the development 
of an adequate degree of beta-receptor blockade in some 
tissues. A sevenfold interpatient variation in plasma levels of 
metoprolol has been reported (19). These characteristics of 
metoprolol could account for the variable reported results. 
In contrast, esmolol, when infused with a loading dose, 
provides stable plasma concentrations within 4 min, with 
rapid dose-dependent beta-receptor blockade. High concen-
trations of esmolol (4 p.g/ml) have been seen when it is given 
at a loading dose of 500 p.glkg per min for 4 min followed by 
a 300 p.glkg per min maintenance infusion. This concentra-
tion can be maintained throughout the infusion. Its effects 
also dissipate rapidly, as demonstrated by increased levels of 
its metabolite ASL-8123, in a dose-dependent fashion 
(19,20). These properties make esmolol a more dependable 
and safe beta-blocker during the head-up tilt test. 
It is difficult to estimate the exact oral dose of metoprolol 
that will be effective in an individual patient. There is no 
persistent interpatient correlation between the dosage of 
metoprolol and the therapeutic response (21) , and titration of 
the metoprolol dose, which might be useful in patients with 
hypertension or angina, may not be practical in patients with 
neurocardiogenic syncope. However, 50 mg twice daily 
seems to be an adequate dose in patients with neurocardio-
genic dysfunction because results with this dose of oral 
metoprolol correlated favorably with results with esmolol, 
which was given at a very high dose. 
Conclusions. In the electrophysiologic laboratory, es-
molol can accurately predict the head-up tilt response to oral 
metoprolol. This information can be useful in formulating an 
appropriate therapeutic strategy at the initial head-up tilt test 
in patients with neurocardiogenic syncope. Patients with a 
negative head-up tilt test response can be safely treated with 
metoprolol. However, in patients who continue to demon-
strate a positive response with esmolol challenge, alternative 
JACC Vol. 19, No. 2 
February 1992:402-8 
treatment strategies could be considered. Otherwise, these 
patients should be closely monitored while taking oral me-
toprolol because the long-term clinical efficacy of beta-
blockers under these circumstances is not clear. 
We are indebted to Barbara Alexander and Brian Miller for their valuable help 
in preparation of the manuscript. 
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